Nkarta (NKTX) Total Current Liabilities (2019 - 2026)
Nkarta's quarterly Total Current Liabilities came in at $18.2 million in Q1 2026, down 2.93% year-on-year from $18.8 million in Q1 2025, and down 18.23% quarter-over-quarter from $22.3 million in Q4 2025.
Nkarta has reported Total Current Liabilities for 8 years, with the latest figure at $18.2 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 2.93% year-over-year to $18.2 million; the trailing twelve-month figure through Mar 2026 stood at $18.2 million (down 2.93% YoY), and the FY2025 full-year result was $22.3 million, up 17.7% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $18.2 million, down from $22.3 million in the prior quarter.
- The five-year high for Total Current Liabilities was $26.6 million in Q2 2023, with the low at $10.8 million in Q1 2022.
- Average Total Current Liabilities over 5 years is $20.9 million, with a median of $22.0 million recorded in 2022.
- Year-over-year, Total Current Liabilities soared 139.63% in 2023 and slipped 21.61% in 2024.
- Tracing NKTX's Total Current Liabilities over 5 years: stood at $22.0 million in 2022, then increased by 5.82% to $23.3 million in 2023, then slipped by 18.92% to $18.9 million in 2024, then gained by 17.7% to $22.3 million in 2025, then dropped by 18.23% to $18.2 million in 2026.
- The last three Total Current Liabilities figures came in at $18.2 million (Q1 2026), $22.3 million (Q4 2025), and $19.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 18.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.21 Mn |
| Dec 31, 2025 | 22.27 Mn |
| Sep 30, 2025 | 18.99 Mn |
| Jun 30, 2025 | 18.93 Mn |
| Mar 31, 2025 | 18.76 Mn |
| Dec 31, 2024 | 18.92 Mn |
| Sep 30, 2024 | 22.47 Mn |
| Jun 30, 2024 | 20.86 Mn |
| Mar 31, 2024 | 22.19 Mn |
| Dec 31, 2023 | 23.33 Mn |
| Sep 30, 2023 | 25.64 Mn |
| Jun 30, 2023 | 26.61 Mn |
| Mar 31, 2023 | 25.98 Mn |
| Dec 31, 2022 | 22.05 Mn |
| Sep 30, 2022 | 26.43 Mn |
| Jun 30, 2022 | 13.18 Mn |
| Mar 31, 2022 | 10.84 Mn |
| Dec 31, 2021 | 12.94 Mn |
| Sep 30, 2021 | 12.05 Mn |
| Jun 30, 2021 | 10.26 Mn |
| Mar 31, 2021 | 9.35 Mn |
| Dec 31, 2020 | 8.83 Mn |
| Sep 30, 2020 | 9.56 Mn |
| Jun 30, 2020 | 59.74 Mn |
| Dec 31, 2019 | 8.17 Mn |